gid - rated as outperform

GID - CIMB Securities rates the stock as Outperform

BY BROKER NEWS - 20/06/2013

• GID - GI DYNAMICS, INC

Target $1.85 (was $1.90). The broker notes the French Government will pay for a clinical study of the company's EndoBarrier treatment. This is the second study they have paid for, with the new work not so much about efficacy, but rather an investigation into potential price and reimbursement levels based on patient outcomes versus traditional treatment.

This is a big endorsement, says CIMB, who notes the news not only takes a bit of pressure off of cash utilisation metrics, but also marks an important milestone in gaining national reimbursement in a key EU market. The Outperform call is maintained, the broker seeing a "compelling investment opportunity".

Sector: Health Care Equipment & Services.

Target price is $1.85.Current Price is $0.60. Difference: $1.25 - (brackets indicate current price is over target). If GID meets the CIMB Securities target it will return approximately 68% (excluding dividends, fees and charges - negative figures indicate an expected loss).